Cellectar Biosciences Inc
CLRB4.930USD
+0.210+4.45%
시장 운영 시간 （ET）시세는 15분 지연됩니다
7.57M시가총액
손실P/E TTM
자세한 내용은 Cellectar Biosciences Inc 회사
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
회사 정보
종목 코드 CLRB
회사 이름Cellectar Biosciences Inc
상장일May 20, 2005
CEOMr. James V. Caruso
직원 수11
유형Ordinary Share
회계 연도 종료May 20
주소100 Campus Drive
도시FLORHAM PARK
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호07932
전화16084418120
웹사이트https://www.cellectar.com/
종목 코드 CLRB
상장일May 20, 2005
CEOMr. James V. Caruso
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Mr. John P. Neis
Mr. John P. Neis
Independent Director
Independent Director
--
--
Dr. Asher Alban Chanan-Khan, M.D.
Dr. Asher Alban Chanan-Khan, M.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Jul 26
마지막 업데이트: Sat, Jul 26
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
주주
주주
비율
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
주주 유형
주주
비율
Investment Advisor
3.70%
Individual Investor
1.91%
Investment Advisor/Hedge Fund
1.28%
Hedge Fund
1.21%
Corporation
0.36%
Research Firm
0.23%
Venture Capital
0.13%
Bank and Trust
0.03%
Other
91.15%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
84
202.41K
7.72%
-340.14K
2025Q1
86
199.12K
11.22%
-346.61K
2024Q4
85
5.89M
13.20%
-10.24M
2024Q3
82
15.21M
37.53%
+860.01K
2024Q2
87
12.77M
37.42%
+1.31M
2024Q1
84
10.31M
32.95%
-1.69M
2023Q4
71
9.17M
43.97%
+2.46M
2023Q3
74
3.14M
32.62%
+389.97K
2023Q2
83
3.71M
38.83%
+394.07K
2023Q1
91
3.81M
40.21%
+165.83K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
57.40K
2.14%
-172.00
-0.30%
Mar 31, 2025
UBS Financial Services, Inc.
29.84K
1.11%
+17.42K
+140.12%
Mar 31, 2025
Adar1 Capital Management LLC
18.19K
0.68%
+16.85K
+1256.45%
Apr 17, 2025
Lytton (Laurence W)
16.78K
0.63%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
14.78K
0.55%
+3.08K
+26.38%
Mar 31, 2025
Longcor (Jarrod)
2.77K
0.18%
+1.00K
+56.47%
Apr 17, 2025
Squarepoint Capital LLP
12.36K
0.46%
-4.98K
-28.71%
Mar 31, 2025
Caruso (James V)
1.64K
0.11%
--
--
Apr 17, 2025
Citadel Advisors LLC
11.44K
0.43%
+11.44K
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
비율0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
날짜
유형
비율
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
